A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2013

At a glance

  • Drugs Alagebrium chloride (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms BREAK; BREAK-DHF-1; BREAK-DHF-I
  • Most Recent Events

    • 05 Aug 2013 ClinicalTrials.gov record NCT01913301 integrated.
    • 05 Aug 2013 ClinicalTrials.gov record NCT01913301 integrated.
    • 02 Feb 2009 Status changed from recruiting to discontinued, based on information from ClinicalTrials.gov. This trial was terminated due to financial contraints.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top